07630 英派藥業－Ｂ
IMPACT THERAP-B
IMPACT THERAP-B
| Register Close | 2026/05/08 IPO Closing in 3 Days |
| Listing Date | 2026/05/13 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Impact Therapeutics, Inc. was founded in 2009, it is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.
--
As of April 26, 2026, the Group’s pipeline consisted of one self-developed Core Product, senaparib, which has been commercialized in China in January 2025 as a first-line (1L) maintenance therapy for ovarian cancer (OC) across all patient populations regardless of mutation status and eleven other self-developed drug candidates (including four clinical-stage and seven preclinical candidates), encompassing emerging modalities such as novel antibody-drug conjugates (ADCs) and degrader candidates.
--
As of April 26, 2026, the Group owned (including solely-owned and co-owned with Eikon) 23 granted patents in China, 19 granted patents in the United States, 29 granted patents in other jurisdictions, and 158 pending patent applications. The Group’s revenue was derived from out-licensing revenue and the sales of pharmaceutical products.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 41.98M H shares |
| No. of International Offer Shares | 37.78M H shares |
| No. of HK Offer Shares | 4.20M H shares |
| Offer Price | $19.75 - $21.75 |
| Stock Code | 7630 |
| Sponsor(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, Tiger Brokers (HK) Global Limited |
TIME TABLE
| Application Period | May 05 (Tue) - noon, May 08 (Fri) |
| Price Determination Date | May 11 (Mon) |
| Result Announcement Date | On or before May 12 (Tue) |
| Result Announcement Date | On or before May 12 (Tue) |
| Result Announcement Date | On or before May 13 (Wed) |
| Dealings in Shares commence on | May 13, 2026. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $19.75 - $21.75 |
| Capitalization | 5.45B - 6.01B |
| NAV / share ($) | $2.83 - $3.12 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 20.75, the net proceeds raised would be HKD 781.00M, of which |
| 51% : Fund clinical development, regulatory approval as well as commercialization of Core Product, senaparib |
| 31% : Ongoing clinical development of Key Products, IMP1734 and IMP9064 |
| 8% : Development activities for other pipeline assets |
| 8% : Development of R&D platforms and expand drug pipeline |
| 2% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).